Biotech’s newborn unicorn Sana grabs Harvard tech aimed at slipping engineered stem cells past the immune system
After leading one of the early pioneers in customized cancer therapies using patient cells for CAR-T, the founding execs at Sana Biotechnology are now nailing down the IP for a new generation of off-the-shelf cell therapies that they believe can have built-in protection against an immune response. And they’re throwing in some open access tech on gene editing to boot.
Basic subscription required
Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.